34results about How to "Less insoluble particles" patented technology

The invention belongs to the technical field of high molecular materials and in particular relates to a medical freeze-dried sterile polyethylene film and a preparation method thereof. The medical freeze-dried sterile polyethylene film is prepared from the following raw materials in parts by weight: 6 to 8 parts of ultrahigh molecular weight polyethylene resin and 2 to 4 parts of metallocene polyethylene. The preparation method of the medical freeze-dried sterile polyethylene film comprises the steps of mixing, preparing the film, cutting the film, packaging and sterilizing. The polyethylene film provided by the invention has the characteristics of low temperature resistance, sterile performance, low insoluble particles, strong mechanical properties and the like, and can meet the freeze-dried production requirements of medicines, crude drugs, biological products, medical intermediates, chemical products and the like.

The invention belongs to the technical field of medicines and particularly relates to a drug composition of bortezomib and a preparation method thereof. The drug composition disclosed by the invention contains bortezomib, tert butyl alcohol, sodium chloride and an excipient in the mass ratio of 1:0.5:(1-5):(5-20). The drug composition adopts freeze-dried powder injection or water injection, preferably the freeze-dried powder injection. The drug composition contains tert butyl alcohol and sodium chloride besides the conventional excipient; through adding tert butyl alcohol, bortezomib can be rapidly dissolved and rapidly reacted with polyalcohol excipients such as mannitol to form more stable borate, so that the stability problem of the bortezomib freeze-dried powder injection per se is solved; and through adding the drug active constituent i.e. sodium chloride, the normal physiological and biochemical activities and functions in vivo are fully guaranteed.

The invention relates to (S)-Pantoprazole sodium lyophilized powder preparation for injection, made from an active ingredient (S)-pantoprazole sodium, a stabilizer and a lyophilizing protectant, wherein the stabilizer is one of sulfobutyl ether-Beta-cyclodextrin, hydroxypropyl- Beta-cyclodextrin, and glucosyl-Beta-cyclodextrin. After the (S)-pantoprazole sodium lyophilized powder preparation for injection is placed for 24 months, R-configuration isomers are less than 0.3%; the number of insoluble microparticles is significantly decreased through optimization of a preparation process; the preparation process is simple and feasible and is suitable for industrial large-scale production.

The invention discloses a steam ejector for vinegar production. The steam ejector for the vinegar production comprises a steam nozzle, a suction chamber, a diffusion tube, an ejector pump, a mixing tank, an underflow pump, an ejection liquefier, a maintaining tank and a liquefaction tank which are sequentially connected. The steam ejector for the vinegar production has the superior effects as follows: liquefaction and gelatinization of a continuous ejection liquefaction method for the steam ejector for the vinegar production are performed in a closed container, so that the steam consumption is low, the heat loss is low, energy can be saved, the use amount of fuel coal is reduced, and the use amount of amylase can be reduced properly; moreover, the liquefaction quality of rice starch milk is not influenced, and the use amount of liquifying enzyme is reduced to 0.4L per ton of saccharide from 0.6L per ton of saccharide originally; with the adoption of the continuous ejection liquefaction method, continuous production of a saccharification process is realized, and the saccharification production environment is improved; due to the good effect of the continuous ejection liquefaction method, a saccharification liquid contains few insoluble particles, and the saccharification quality is improved.

The invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and its preparing process, wherein the composition comprises breviscapine and Radix Astragali saponin with a purity of over 80% extracted from astragalus root, the content of the Radix Astragali saponin being 20-30%.

The invention belongs to the technical field of transfer boxes, and discloses a special intravenous injection drug transfer box for an intravenous drug use configuration center. The special intravenous injection drug transfer box comprises a multi-layer box body and a box cover, the upper ends and the lower ends of both sides of the box body integrally form mutually matched buckles, and a handle is connected to the middle of the box cover in a bolted mode. Two parallel detachable soft clamps are connected into the box body in a clamped mode, and buckles matched with the upper side of the box body are separately and integrally formed on both sides of the box cover. According to the special intravenous injection drug transfer box for the intravenous drug use configuration center, liquid leakage of drugs caused by collision of a piston can be avoided and mutual contamination of syringes due to moving contact can be avoided, the number of drug groups can be directly counted without openingthe cover during transportation and handover, all components are detachable, and thorough cleaning and disinfection are facilitated.

The invention belongs to the technical field of medicines, and particularly relates to a dantrolene sodium freeze-dried powder injection for injection and a preparation method thereof. The freeze-dried powder injection is prepared by freeze drying dantrolene sodium, lactobiose, a pH regulator and water for injection, wherein a mass ratio of the dantrolene sodium to the lactobiose is (1:0.5) to (1:2.5). The preparation method comprises the following steps of: adding the dantrolene sodium to the lactobiose in a prescription amount into the water for the injection, stirring, regulating the pH value to 9.0 to 10.5 by using the pH regulator, adding active carbon for injection, removing a heat source, decolorizing, filtering for decarburizing, performing fine filtering by using a filter membrane, packaging in separate bags, freezing and drying. The dantrolene sodium freeze-dried powder injection is studied on the basis of a freeze-dried process, namely the dantrolene sodium freeze-dried powder injection is cooled, heated by a small margin and is cooled again, so that the moisture of the freeze-dried product is reduced, and the freeze-dried product is high in redissolution and visible foreign matters and does not have insoluble granules. The dantrolene sodium freeze-dried powder injection for the injection is high in resolubility, clarity and stability, and low impurity content.

The invention relates to a muscular amino acid and nucleoside extract containing polypeptide, amino acid, nucleoside, nucleotide and other medicinal components. The extract is prepared by crushing cardiac muscles and muscles of a rabbit of which the connective tissue is removed to be mixed with water, homogenizing, freeing and performing ultrasonic treatment; adding potassium chloride into the homogenate, and performing ultrasonic agitation; and centrifuging to obtain supernate, filtering with a filter membrane, and performing ultrafiltration. The invention also provides a muscular amino acid and nucleoside medicinal composition injection and lyophilized powder, wherein the muscular amino acid and nucleoside medicinal composition consists of the following components: 1000ml of muscular amino acid and nucleoside solution, 1.5g of sorbitol, 0.2g of thioglycerol, and 1.0g of poloxamer 188; and the concentration of the polypeptide in the muscular amino acid and nucleoside solution is between 1.58 and 1.92mg / ml, and the concentration of hypoxanthine is between 0.22 and 0.28mg / ml. The muscular amino acid and nucleoside pharmaceutical composition lyophilized powder is prepared by lyophilizing 1,000ml of muscular amino acid and nucleoside solution, 40g of dextran 40, 0.2g of thioglycerol, 1.0g of poloxamer 188, and 0.5g of hydroxypropyl betadex. The muscular amino acid and nucleoside extract and the pharmaceutical composition thereof have a good effect of improving the stability of muscular amino acid and nucleoside and maintaining low insoluble particles.

The invention discloses a high-purity mezlocillin sodium preparation. The high-purity mezlocillin sodium preparation comprises uniform granules with the grain sizes smaller than 50 micrometers. The content of total impurities in the high-purity mezlocillin sodium preparation is lower than or equal to 0.68%, and the content of polymers in the high-purity mezlocillin sodium preparation is lower than or equal to 0.06%. The invention further discloses a method for preparing the high-purity mezlocillin sodium preparation. The method includes six steps of preparing ampicillin sodium solution; preparing mezlocillin sodium condensation liquid; preparing mezlocillin dry powder; preparing mezlocillin sodium solution; preparing mezlocillin sodium active compounds; preparing the high-purity mezlocillin sodium preparation. The high-purity mezlocillin sodium preparation and the method have the advantages that existing problems can be solved by the aid of the high-purity mezlocillin sodium preparation prepared by the aid of novel crystallization technologies, and the quality of the high-purity mezlocillin sodium preparation can be greatly improved; the high-purity mezlocillin sodium preparation is high in dissolving rate and purity, low in impurity content and insoluble particle content, good in flowability and easy to separately package, and the like.

The invention belongs to the technical field of biomedicine, and particularly relates to a preparation method of a levocarnitine injection preparation. The injection preparation is prepared from raw auxiliary materials including levocarnitine, proline and a pH adjuster; the preparation method solves the problems that in the prior art, in the process of preparing injection levocarnitine, the stability of a preparation is poor, impurities are generated after long-term placement, and the quality requirements in the duration of validity cannot be met; a more reliable technical support is providedfor the use of injection levocarnitine.

The invention belongs to the technical field of medicine, and relates to a corimycin freeze-dried powder preparation and a preparation method thereof. The freeze-dried powder preparation is prepared by corimycin, an organic acid or an inorganic acid, a proppant and water for injection. to make. Wherein, every 1000ml of water for injection contains 40-115g of corimycin, 20-100g of organic acid or inorganic acid, and 15-30g of proppant. The weight ratio of carrimycin, organic acid or inorganic acid is: 1:1-5:1, preferably 2:1-4:1. Inorganic acid includes hydrochloric acid, sulfuric acid or phosphoric acid; described organic acid includes citric acid, anhydrous citric acid, maleic acid, adipic acid, acetic acid, methanesulfonic acid, ethanesulfonic acid, fumaric acid, tartaric acid, apple Acid, pyroglutamic acid, lactic acid, succinic acid or C1-C4 straight chain or branched chain alkane sulfonate unsubstituted or substituted by any position of 1-3 hydroxyl groups. The freeze-dried powder injection of the invention has the characteristics of short reconstitution time, few insoluble particles, easy preparation and relatively stable characteristics.

The invention discloses a stephanine hydrochloride freeze-dried powder, which comprises stepherine hydrochloride and freeze-drying excipients, and the excipients include trehalose, lactose and sorbitol. The content of stephanine hydrochloride in the freeze-dried powder of the present invention reaches the selection of scalar components and proportions, so that the stability of the freeze-dried powder is good, the bioavailability is high, and the frequency and frequency of medication for patients are reduced. The clinical effect is good, and the validity period is prolonged compared with the prior art. The water content of the products obtained in the present invention is all lower than 3%. In addition, the freeze-dried powder prepared by the preferred technical solution of the present invention will not produce a large amount of fine powder and will not stick to the container wall. Regardless of whether water for injection, sodium chloride injection or glucose injection is used, the stephine hydrochloride freeze-dried powder of the present invention can be quickly dissolved, and the dissolution speed is fast and the insoluble particles are few.

The invention relates to a sterile freeze-dried powder of S-pantoprazole sodium for injection, comprising active ingredient S-pantoprazole sodium, a stabilizer, and a freeze-drying protective agent; wherein the stabilizer is sulfobutyl-β One of ‑cyclodextrin, hydroxypropyl‑β‑cyclodextrin, glucosyl‑β‑cyclodextrin. The R-configuration isomer of the product of the present invention is less than 0.3% after 24 months of storage; the number of insoluble particles is significantly reduced through the optimization of the preparation process; the preparation process of the present invention is simple and easy, and is suitable for industrial scale production.

An L-oxiracetam hydro-acupuncture for injection is disclosed. According to the invention, 58-72% of L-oxiracetam, 8-22% of glycerin, 13-25% of glycine, 3-8% of vitamin C, 2-5% of ethylene diamine tetraacetic acid and 1-3% of benzyl alcohol which are used as raw materials and auxiliary materials undergo steps of concentrated mixing, diluted mixing, encapsulation, sterilization, inspection and packaging to prepare the L-oxiracetam hydro-acupuncture for injection. During the sterilization process of the L-oxiracetam hydro-acupuncture for injection, pH value of the solution is barely changed, the product is not easy to oxidize, and impurity increasing amount is only 0.02% during the sterilization process. Dissolvability of main drug of the product is good. Insoluble particles are lower than 25 microns. Stability is good. The period of validity is as long as 18 months and above. The product has less impurity during the period of validity, and the total impurity content is lower than 0.28%. Pains of patients are obviously reduced during the injection process, and patients' compliance is good. The product is worthy of market promotion.

The invention discloses a preparation method of chlorinated rubber. The preparation method includes the steps that firstly, natural rubber is added into a reaction kettle containing reaction media and auxiliaries, stirring is performed for 10-20 min, the weight ratio of natural rubber to the reaction media and to the auxiliaries is 1: (10-15): (0.02-0.15), and the reaction media are a hydrochloric acid solution with the mass fraction being 10-15%; secondly, chlorine is added into the reaction kettle, a chlorination reaction is performed, a coarse chlorinated rubber product is obtained, and a chlorination reaction condition includes that firstly reaction is performed at 90-110 DEG C for 2-3 h, and then reaction is performed at 50-70 DEG C for 2-3 h; thirdly, the coarse chlorinated rubber product obtained in the second step is subjected to deacidifying treatment, and chlorinated rubber is obtained through drying. The chlorinated evenness degree is high, the chlorination degree is high, product transparency is high, and solubility is good.

The invention discloses a composition containing ibutilide fumarate and a preparation method and application thereof. The pH value of the composition containing ibutilide fumarate is smaller than 4.0. The preparation method comprises the step of adjusting the pH value of the composition to a set pH value by utilizing a pH regulating agent. The application refers to the application of the composition containing ibutililde fumarate in preparing antiarrhythmic drugs. The composition containing ibutilide fumarate has good thermal stability and has little change on the content of the ibutilide fumarate and reduction of impurities after sterilized.

The invention provides a rabeprazole sodium composition which comprises the active ingredients of rabeprazole, mannitol and ethylene diamine tetraacetic acid, wherein the weight ratio of ethylene diamine tetraacetic acid to rabeprazole sodium is 0.05-0.5:1. The method for preparing the composition into solid powder-needle preparation comprises the following steps: dissolving the ethylene diamine tetraacetic acid solution with the prescription amount into injection water, adding and stirring the rabeprazole sodium with the prescription amount at a temperature of 25-35 DEG C for dissolving, then adding mannitol with the prescription amount, stirring the mannitol for dissolving, cooling to a room temperature, and regulating the pH value of the solution to 11.5-12.5; adding active carbon into the confected solution, stirring and filtering for decarburization, and freezing and drying the obtained filtrate to obtain the rabeprazole frozen powder needle. The rabeprazole frozen powder needle has full appearance, favorable stability and solubility and little insoluble grains in the injection.

The invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and its preparing process, wherein the composition comprises breviscapine and Radix Astragali saponin with a purity of over 80% extracted from astragalus root, the content of the Radix Astragali saponin being 20-30%.